Triazine dendrimers as drug delivery systems: From synthesis to therapy

Advanced Drug Delivery Reviews

Volumn 64, Issue 9, 2012, Pages 826-835

  Lim, Jongdoo ^a   Simanek, Eric E ^a  

^a TEXAS CHRISTIAN UNIVERSITY   (United States)

Author keywords

Camptothecin; Chemotherapy; DNA; Drug delivery; Glucose sensing; Iron overload; Paclitaxel; Pharmacokinetics; RNAi; Septic shock; Triazine dendrimer

Indexed keywords

CAMPTOTHECIN (CPT); GLUCOSE SENSING; IRON-OVERLOAD; PACLITAXEL; RNAI; SEPTIC SHOCKS;

BODY FLUIDS; CHEMOTHERAPY; DNA; DRUG DELIVERY; GLUCOSE; GLUCOSE SENSORS; PHARMACOKINETICS; RNA; SIGNAL TRANSDUCTION;

DENDRIMERS;

BREFELDIN A; CAMPTOTHECIN; DEFEROXAMINE; DENDRIMER; GLUCOSE; MACROGOL; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; PRODRUG; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 4; TRIAZINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVANCED CANCER; ADVERSE OUTCOME; BIOSENSOR; BIOSYNTHESIS; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DIABETES MELLITUS; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; DRUG SOLUBILITY; ENCAPSULATION; ESOPHAGUS CANCER; GENE TARGETING; HEAD AND NECK CANCER; HEMOCHROMATOSIS; IC 50; IN VITRO STUDY; IN VIVO STUDY; IRON OVERLOAD; KAPOSI SARCOMA; LUNG CANCER; METASTASIS; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PARTICLE SIZE; PRIORITY JOURNAL; PROSTATE CANCER; REACTION TIME; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; TREATMENT PLANNING;

ANIMALS; DENDRIMERS; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; TOLL-LIKE RECEPTOR 4; TRIAZINES;

EID: 84861226527     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.03.008     Document Type: Review

References (82)

1. Astruc D., Boisselier E., Ornelas C. Dendrimers designed for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedicine. Chem. Rev. 2010, 110:1857-1959.
2. Svenson S., Tomalia D.A. Dendrimers in biomedical applications-reflections on the field. Adv. Drug Deliv. Rev. 2005, 57:2106-2129.
3. Fréchet J.M. Functional polymers and dendrimers: reactivity, molecular architecture, and interfacial energy. Science 1994, 263:1710-1715.
4. Röglin L., Lempens E.H., Meijer E.W. A synthetic "tour de force": well-defined multivalent and multimodal dendritic structures for biomedical applications. Angew. Chem. Int. Ed Engl. 2011, 50:102-112.
5. D'Emanuele A., Attwood D. Dendrimer-drug interactions. Adv. Drug Deliv. Rev. 2005, 57:2147-2162.
6. Zeng F., Zimmerman S.C. Dendrimers in supramolecular chemistry: from molecular recognition to self-assembly. Chem. Rev. 1997, 97:1681-1712.
7. Medina S.H., El-Sayed M.E. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem. Rev. 2009, 109:3141-3157.
8. Dichtel W.R., Serin J.M., Edder C., Fréchet J.M., Matuszewski M., Tan L.S., Ohulchanskyy T.Y., Prasad P.N. Singlet oxygen generation via two-photon excited FRET. J. Am. Chem. Soc. 2004, 126:5380-5381.
9. Majoros I.J., Williams C.R., Baker J.R. Current dendrimer applications in cancer diagnosis and therapy. Curr. Top. Med. Chem. 2008, 8:1165-1179.
10. Godin B., Tasciotti E., Liu X., Serda R.E., Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc. Chem. Res. 2011, 44:979-989.
11. Joshi N., Grinstaff M. Applications of dendrimers in tissue engineering. Curr. Top. Med. Chem. 2008, 8:1225-1236.
12. Lee C.C., MacKay J.A., Fréchet J.M., Szoka F.C. Designing dendrimers for biological applications. Nat. Biotechnol. 2005, 23:1517-1526.
13. Satija J., Sai V.V.R., Mukherji S. Dendrimers in biosensors: concept and applications. J. Mater. Chem. 2011, 21:14367-14386.
14. Martić S., Labib M., Shipman P.O., Kraatz H.B. Ferrocene-peptido conjugates: from synthesis to sensory applications. Dalton Trans. 2011, 40:7264-7290.
15. Chouai A., Simanek E.E. Kilogram-scale synthesis of a second generation dendrimer based on 1,3,5-triazine using green and industrially compatible methods with a single chromatographic step. J. Org. Chem. 2008, 73:2357-2366.
16. Chouai A., Venditto V.J., Simanek E.E., Vanderplas B.C., Ragan J.A. Large scale, green synthesis of a generation-1 melamine (triazine) dendrimer. Organic Synth. 2009, 86:151.
17. Chouai A., Venditto V.J., Simanek E.E., McDermott R.E., Ragan J.A. Synthesis of 2-[3,3'-di-(tert-butoxycarbonyl)-aminodipropylamine]-4,6,-dichloro-1,3,5-triazine as a monomer and 1,3,5-[tris-piperazine]-triazine as a core for the large scale synthesis of melamine (triazine) dendrimers. Organic Synth. 2009, 86:141-150.
18. Lim J., Mintzer M.A., Perez L.M., Simanek E.E. Synthesis of odd generation triazine dendrimers using a divergent, macromonomer approach. Org. Lett. 2010, 12:1148-1151.
19. Lim J., Pavan G.M., Annunziata O., Simanek E.E. Experimental and computational evidence for an inversion in guest capacity in high-generation triazine dendrimer hosts. J. Am. Chem. Soc. 2012, 134:1942-1945.
20. Simanek E.E., Abdou H., Lalwani S., Lim J., Mintzer M., Venditto V.J., Vittur B. The 8 year thicket of triazine dendrimers: strategies, targets and applications. Proc. R. Soc. A 2010, 466:1445-1468.
21. Moreno K.X., Simanek E.E. Identification of diamine linkers with differing reactivity and their application in the synthesis of melamine dendrimers. Tetrahedron Lett. 2008, 49:1152-1154.
22. Steffensen M.B., Simanek E.E. Chemoselective building blocks for dendrimers from relative reactivity data. Org. Lett. 2003, 5:2359-2361.
23. Moreno K.X., Simanek E.E. Conformational analysis of triazine dendrimers: using NMR spectroscopy to probe the choreography of a dendrimer's dance. Macromolecules 2008, 41:4108-4114.
24. Steffensen M.B., Hollink E., Kuschel F., Bauer M., Simanek E.E. Dendrimers based on [1,3,5]-triazines. J. Polym. Sci. A 2006, 44:3411-3433.
25. Zhang W., Simanek E.E. Dendrimers based on melamine. Divergent and orthogonal, convergent synthesis of a G3 dendrimer. Org. Lett. 2000, 2:843-845.
26. Zhang W., Nowlan D.T., Thomson L.M., Lackowski W.M., Simanek E.E. Orthogonal, convergent syntheses of dendrimers based on melamine with one or two unique surface sites for manipulation. J. Am. Chem. Soc. 2001, 123:8914-8922.
27. Lim J., Simanek E.E. Toward the next-generation drug delivery vehicle: synthesis of a dendrimer with four orthogonally reactive groups. Mol. Pharmaceutics 2005, 2:273-277.
28. Steffensen M.B., Simanek E.E. Synthesis and manipulation of orthogonally protected dendrimers: building blocks for library synthesis. Angew. Chem. Int. Ed. 2004, 43:5178-5180.
29. Umali A.P., Crampton H.L., Simanek E.E. Triazine dendrimers with orthogonally protected amines on the periphery. Masking amines with Dde and BOC groups provides an alternative to carrying protected alcohols and disulfides through an iterative synthesis. J. Org. Chem. 2007, 72:9866-9874.
30. Umali A.P., Simanek E.E. Thiol-disulfide exchange yields multivalent dendrimers of melamine. Org. Lett. 2003, 5:1245-1247.
31. Zhang W., Tichy S.E., Perez L.M., Maria G.C., Lindahl P.A., Simanek E.E. Evaluation of multivalent dendrimers based on melamine: kinetics of thiol-disulfide exchange depends on the structure of the dendrimer. J. Am. Chem. Soc. 2003, 125:5086-5094.
32. Crampton H., Hollink E., Perez L.M., Simanek E.E. A divergent route towards single-chemical entity triazine dendrimers with opportunities for structural diversity. New J. Chem. 2007, 31:1283-1290.
33. Hollink E., Simanek E.E. A divergent route to diversity in macromolecules. Org. Lett. 2006, 8:2293-2295.
34. Mintzer M.A., Perez L.M., Simanek E.E. Divergent synthesis of triazine dendrimers using a trimethylene-dipiperidine linker that increases efficiency, simplifies analysis, and improves product solubility. Tetrahedron Lett. 2010, 51:1631-1634.
35. Lim J., Simanek E.E. Synthesis of water-soluble dendrimers based on melamine bearing 16 paclitaxel groups. Org. Lett. 2008, 10:201-204.
36. Lim J., Chouai A., Lo S.T., Liu W., Sun X., Simanek E.E. Design, synthesis, characterization, and biological evaluation of triazine dendrimers bearing paclitaxel using ester and ester/disulfide linkages. Bioconjugate Chem. 2009, 20:2154-2161.
37. Lo S.T., Stern S., Clogston J.D., Zheng J., Adiseshaiah P.P., Dobrovolskaia M., Lim J., Patri A.K., Sun X., Simanek E.E. Biological assessment of triazine dendrimer: toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct. Mol. Pharmaceutics 2010, 7:993-1006.
38. Lim J., Lo S.T., Hill S., Pavan G.M., Sun X., Simanek E.E. Antitumor activity and molecular dynamics simulations of paclitaxel-laden triazine dendrimers. Mol. Pharmaceutics 2012, 9:404-412.
39. Lim J., Venditto V.J., Simanek E.E. Synthesis and characterization of a triazine dendrimer that sequesters iron(III) using 12 desferrioxamine B groups. Bioorg. Med. Chem. 2010, 18:5749-5753.
40. Cummin B.M., Lim J., Simanek E.E., Pishko M.V., Coté G.L. Encapsulation of a concanavalin A/dendrimer glucose sensing assay within microporated poly (ethylene glycol) microspheres. Biomed. Opt. Express 2011, 2:1243-1257.
41. Venditto V.J., Allred K., Allred C.D., Simanek E.E. Intercepting the synthesis of triazine dendrimers with nucleophilic pharmacophores: a general strategy toward drug delivery vehicles. Chem. Commun. 2009, 7:5541-5542.
42. Duncan R., Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 2005, 57:2215-2237.
43. Chen H.-T., Neerman M.F., Parrish A.R., Simanek E.E. Cytotoxicty, hemolysis and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J. Am. Chem. Soc. 2004, 126:10044-10048.
44. Neerman M.F., Chen H.-T., Parrish A.R., Simanek E.E. Reduction of drug toxicity using dendrimers based on melamine. Mol. Pharmaceutics 2004, 1:390-393.
45. Neerman M.F., Zhang W., Parrish A.R., Simanek E.E. In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery. Int. J. Pharm. 2004, 281:129-132.
46. Neerman M.F., Umali A.P., Chen H.-T., Waghela S.D., Parrish A.R., Simanek E.E. Biological evaluation of dendrimers based on melamine. J. Drug Del. Sci. Tech. 2005, 15:31-40.
47. Zhang W., Jiang J., Qin C., Thomson L.M., Parrish A.R., Safe S.H., Simanek E.E. Triazine dendrimers for drug delivery: evaluation of solubilization properties, activity in cell culture, and in vivo toxicity of a candidate vehicle. Supramol. Chem. 2003, 15:607-615.
48. Gillies E.R., Dy E., Fréchet J.M.J., Szoka F.C. Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. Mol. Pharmaceutics 2005, 2:129-138.
49. Lim J., Guo Y., Rostollan C.L., Stanfield J., Hsieh J.-T., Sun X., Simanek E.E. The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers. Mol. Pharmaceutics 2008, 5:540-547.
50. Kaminskas L.M., Boyd B.J., Karellas P., Krippner G.Y., Lessene R., Kelly B., Porter C.J.H. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. Mol. Pharmaceutics 2008, 5:449-463.
51. Greish K., Fang J., Inutsuka T., Nagamitsu A., Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin. Pharmacokinet. 2003, 42:1089-1105.
52. Elsabahy M., Nazarali A., Foldvari M. Non-viral nucleic acid delivery: key challenges and future directions. Curr. Drug Deliv. 2011, 8:235-244.
53. Ditto A.J., Shah P.N., Yun Y.H. Non-viral gene delivery using nanoparticles. Expert Opin. Drug Deliv. 2009, 6:1149-1160.
54. Mintzer M.A., Simanek E.E. Nonviral vectors for gene delivery. Chem. Rev. 2009, 109:259-302.
55. Kamimura K., Suda T., Zhang G., Liu D. Advances in gene delivery systems. Pharmaceut. Med. 2011, 25:293-306.
56. Durand S., Cimarelli A. The inside out of lentiviral vectors. Viruses 2011, 3:132-159.
57. Campolongo M.J., Tan S.J., Xu J., Luo D. DNA nanomedicine: engineering DNA as a polymer for therapeutic and diagnostic applications. Adv. Drug Deliv. Rev. 2010, 62:606-616.
58. Mintzer M.A., Merkel O.M., Kissel T., Simanek E.E. Polycationic triazine-based dendrimers: effect of peripheral groups on transfection efficiency. New J. Chem. 2009, 33:1918-1925.
59. Merkel O.M., Mintzer M.A., Sitterberg J., Bakowsky U., Simanek E.E., Kissel T. Triazine dendrimers as nonviral gene delivery systems: effects of molecular structure on biological activity. Bioconjugate Chem. 2009, 20:1799-1806.
60. Merkel O.M., Mintzer M.A., Librizzi D., Samsonova O., Dicke T., Sproat B., Garn H., Barth P.J., Simanek E.E., Kissel T. Triazine dendrimers as nonviral vectors for in vitro and in vivo RNAi: the effects of peripheral groups and core structure on biological activity. Mol. Pharmaceutics 2010, 7:969-983.
61. Pavan G.M., Mintzer M.A., Simanek E.E., Merkel O.M., Kissel T., Danani A. Computational insights into the interactions between DNA and siRNA with "rigid" and "flexible" triazine dendrimers. Biomacromolecules 2010, 11:721-730.
62. Merkel O.M., Zheng M., Mintzer M.A., Pavan G.M., Librizzi D., Maly M., Höffken H., Danani A., Simanek E.E., Kissel T. Molecular modeling and in vivo imaging can identify successful flexible triazine dendrimer-based siRNA delivery systems. J. Control. Release 2011, 153:23-33.
63. Aissaoui A., Oudrhiri N., Petit L., Hauchecorne M., Kan E., Sainlos M., Julia S., Navarro J., Vigneron J.P., Lehn J.M., Lehn P. Progress in gene delivery by cationic lipids: guanidinium-cholesterol-based systems as an example. Curr. Drug Targets 2002, 3:1-16.
64. Padié C., Maszewska M., Majchrzak K., Nawrot B., Caminade A.M., Majoral J.P. Polycationic phosphorus dendrimers: synthesis, characterization, study of cytotoxicity, complexation of DNA, and transfection experiments. New J. Chem. 2009, 33:318-326.
65. Zhang W., Lalwani S., Chouai A., Simanek E.E. Synthesis and characterization of anionic triazine dendrimers with a labile disulfide core. Isr. J. Chem. 2009, 49:23-30.
66. Scripture C.D., Figg W.D., Sparreboom A. Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther. Clin. Risk Manag. 2005, 1:107-114.
67. Crown J., O'Leary M., Ooi W.S. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 2004, 9:24-32.
68. Ali I., Rahis-Uddin K., Salim M.A., Rather W.A., Wani A. Haque, Advances in nano drugs for cancer chemotherapy. Curr. Cancer Drug Targets 2011, 11:135-146.
69. Safavy A. Recent developments in taxane drug delivery. Curr. Drug Deliv. 2008, 5:42-54.
70. Blum J.L., Savin M.A., Edelman G., Pippen J., Robert N.J., Geister B.V., Kirby R.L., Clawson A., O'Shaughnessy J.A. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin. Breast Cancer 2007, 7:850-856.
71. Hawkins M.J., Soon-Shiong P., Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 2008, 60:876-885.
72. Bonomi P. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Rev. Anticancer Ther. 2007, 7:415-422.
73. Feng Z., Zhao G., Yu L., Gough D., Howell S.B. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother. Pharmacol. 2010, 65:923-930.
74. O'Leary J., Muggia F.M. Camptothecins: a review of their development and schedules of administration. Eur. J. Cancer 1998, 34:1500-1508.
75. Zunino F., Pratesi G. Camptothecins in clinical development. Expert Opin. Investig. Drugs 2004, 13:269-284.
76. Barton J.C. Chelation therapy for iron overload. Curr. Gastroenterol. Rep. 2007, 9:74-82.
77. Kontoghiorghes G.J., Eracleous E., Economides C., Kolnagou A. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Curr. Med. Chem. 2005, 12:2663-2681.
78. Hallaway P.E., Eaton J.W., Panter S.S., Hedlund B.E. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:10108-10112.
79. Shaunak S., Thomas S., Gianasi E., Godwin A., Jones E., Teo I., Mireskandari K., Luthert P., Duncan R., Patterson S., Khaw P., Brocchini S. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat. Biotechnol. 2004, 22:977-984.
80. Barata T., Teo I., Lalwani S., Simanek E.E., Zloh M., Shaunak S. Computational design principles for bioactive dendrimer based constructs as antagonists of the TLR4-MD-2-LPS complex. Biomaterials 2011, 32:8702-8711.
81. Moschou E.A., Sharma B.V., Deo S.K., Daunert S. Fluorescence glucose detection: advances toward the ideal in vivo biosensor. J. Fluoresc. 2004, 14:535-547.
82. Cummin B.M., Lim J., Simanek E.E., Pishko M.V., Coté G.L. Encapsulation of a Concanavalin A/dendrimer glucose sensing assay within microporated poly (ethylene glycol) microspheres. Biomed. Opt. Express 2011, 2:1243-1257.